MACROD2

ADP-ribose glycohydrolase MACROD2 · A1Z1Q3 · MACROD2 on Sugi Atlas →

4,268 patent compounds predicted against MACROD2, 4,028 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Diadenosine Tetraphosphate (SCHEMBL849869)	0.93	1/20
SCHEMBL1744586	0.93	1/20
SCHEMBL2934890	0.93	1/20
Diadenosine Tetraphosphate (SCHEMBL4069414)	0.93	1/20
SCHEMBL4357990	0.93	1/20
Diadenosine Tetraphosphate (SCHEMBL4363130)	0.93	1/20
Adenosine Triphosphate (SCHEMBL926531)	0.89	1/20
Adenosine Triphosphate (SCHEMBL926534)	0.89	1/20
Adenosine Triphosphate (SCHEMBL8979)	0.88	1/20
Adenosine Triphosphate (SCHEMBL8980)	0.88	1/20
SCHEMBL376008	0.88	1/20
SCHEMBL376009	0.88	1/20
Adenosine Triphosphate (SCHEMBL468214)	0.88	1/20
Adenosine Triphosphate (SCHEMBL889293)	0.88	1/20
Adenosine Triphosphate (SCHEMBL2227081)	0.88	1/20
Adenosine Triphosphate (SCHEMBL4362224)	0.88	1/20
SCHEMBL4366441	0.88	1/20
Adenosine Triphosphate (SCHEMBL28356)	0.86	1/20
Adenosine Triphosphate (SCHEMBL28358)	0.86	1/20
Atpgammas (SCHEMBL77440)	0.86	1/20

Clinical trials — most relevant to MACROD2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)	PHASE3	COMPLETED
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency	PHASE2/PHASE3	RECRUITING
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies	PHASE1/PHASE2	RECRUITING
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA)	PHASE1/PHASE2	COMPLETED
Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations	PHASE2	ACTIVE_NOT_RECRUITING
Effects of Vitamin B3 in Patients With Ataxia Telangiectasia	PHASE2	COMPLETED
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis	PHASE2	ACTIVE_NOT_RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors	PHASE1/PHASE2	NOT_YET_RECRUITING
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)	PHASE2	ACTIVE_NOT_RECRUITING
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer	PHASE2	COMPLETED
A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin	PHASE2	COMPLETED
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer	PHASE2	ACTIVE_NOT_RECRUITING
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer	PHASE1	COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers	PHASE1	COMPLETED
Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer	PHASE1	UNKNOWN
PET Imaging of PARP Activity in Cancer	EARLY_PHASE1	UNKNOWN
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
Prospective Validation of Prostate Biomarkers for Repeat Biopsy	nan	UNKNOWN
Biomarkers in Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab	nan	COMPLETED
Genetics of Prostate Cancer in Young Patients	nan	COMPLETED
Genomic Analysis of Families With a History of Discordant Cancers	nan	RECRUITING
Study of the Effect of Innate on the Inflammatory Response to Endotoxin	nan	RECRUITING
Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer	nan	NO_LONGER_AVAILABLE
Cervical Thermal Ablation to Treat Persistent HPV Infection	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MACROD2 binder may also engage these)

Protein	Name	Similarity
Q3UYG8	—	1.000	Q3UYG8 →
Q6PAV8	—	0.992	Q6PAV8 →
Q5RD27	—	0.987	Q5RD27 →
Q8WML3	—	0.987	Q8WML3 →
O70551	—	0.987	O70551 →
A6QP06	—	0.986	A6QP06 →
Q5TKR9	—	0.985	Q5TKR9 →
E7F7X0	—	0.985	E7F7X0 →
Q6JP77	—	0.984	Q6JP77 →
SRPK1	SRSF protein kinase 1	0.984	landscape →
Q92613	—	0.983	Q92613 →
PARG	Poly(ADP-ribose) glycohydrolase	0.983	landscape →
C3XRY1	—	0.983	C3XRY1 →
E1C2V1	—	0.983	E1C2V1 →
Q9DDT2	—	0.983	Q9DDT2 →
Q8BMD7	—	0.983	Q8BMD7 →
Q6DFV7	—	0.983	Q6DFV7 →
O15013	—	0.982	O15013 →
Q6IVY4	—	0.982	Q6IVY4 →
Q8TDB6	—	0.982	Q8TDB6 →
Q80ZX8	—	0.982	Q80ZX8 →
B8QB46	—	0.981	B8QB46 →
Q9ULJ8	—	0.981	Q9ULJ8 →
Q8N4S0	—	0.981	Q8N4S0 →
Q8VIJ5	—	0.981	Q8VIJ5 →
A0JMK9	—	0.981	A0JMK9 →
Q8K3E5	—	0.981	Q8K3E5 →
Q5FWF4	—	0.981	Q5FWF4 →
Q80U87	—	0.981	Q80U87 →
Q71M44	—	0.981	Q71M44 →